EUVIMEDEUVIMED entdecken
Crossref

Multiplicity Control in Oncology Clinical Trials With a Binary Surrogate Endpoint‐Based Drop‐The‐Losers Design

Weibin Zhong iD, Jing-Ou Liu, Chenguang Wang

Statistics in Medicine · 2025

DOI: 10.1002/sim.70209 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Statistics in Medicine, 2025. Verfasst von Weibin Zhong und 2 weiteren Autor:innen. Beteiligte Einrichtung: Biostatistics and Data Management, Regeneron Pharmaceuticals, Tarrytown, New York, USA. Hauptthemen laut MEDLINE: Research Design, Endpoint Determination, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic. Die Arbeit nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Typical phase 1 oncology studies identify the maximum tolerated dose as the “optimal” dose for subsequent phases. With the advancement of molecular targeted agents and immunotherapies, however, evaluating two or more doses has become increasingly critical for dose selection. Such evaluation is often done in phase 2 studies in a randomized manner. In this article, we evaluate the strategy of applying an adaptive phase 2/3 seamless design for dose selection in oncology studies. Specifically, we consider the “drop‐the‐losers” design, where multiple treatment arms and a control arm are administered during the initial stage, and a more effective arm is identified for later stages by a binary surrogate endpoint such as overall response. We derive the theoretical type I error inflation scale and conduct simulation studies to illustrate the impact of various factors on the type I error inflation in such designs. Furthermore, we demonstrate the findings through the design of a lung cancer trial and introduce a software that implements the proposed design.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Research DesignEndpoint DeterminationClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicMedical OncologyClinical Trials as TopicHumansComputer SimulationMaximum Tolerated DoseLung NeoplasmsNeoplasmsAntineoplastic AgentsModels, StatisticalBiomarkersRandomized Controlled Trials as TopicSoftware

Stichwörter der Autor:innen

dose selectiondrop‐the‐losers designmultiplicity controlsurrogate endpoint

Substanzen

Antineoplastic AgentsBiomarkers

Autor:innen und Institutionen

  • Biostatistics and Data Management, Regeneron Pharmaceuticals, Tarrytown, New York, USA.

ORCID-Profile: Weibin Zhong

Zitieren

APA

Zhong, W., Liu, J. O., & Wang, C. (2025). Multiplicity Control in Oncology Clinical Trials With a Binary Surrogate Endpoint‐Based Drop‐The‐Losers Design. Statistics in Medicine. https://doi.org/10.1002/sim.70209

Vancouver

Zhong W, Liu JO, Wang C. Multiplicity Control in Oncology Clinical Trials With a Binary Surrogate Endpoint‐Based Drop‐The‐Losers Design. Statistics in Medicine. 2025. doi:10.1002/sim.70209

BibTeX
@article{Zhong2025,
  author = {Zhong, Weibin and Liu, Jing-Ou and Wang, Chenguang},
  title = {Multiplicity Control in Oncology Clinical Trials With a Binary Surrogate Endpoint‐Based Drop‐The‐Losers Design},
  journal = {Statistics in Medicine},
  year = {2025},
  doi = {10.1002/sim.70209}
}
Kostenlos starten →